Literature DB >> 2507922

An explanation for the protective effect of the MHC class II I-E molecule in murine diabetes.

E P Reich1, R S Sherwin, O Kanagawa, C A Janeway.   

Abstract

Insulin-dependent diabetes mellitus is widely believed to be an autoimmune disease. Recent onset diabetics show destruction of insulin-secreting pancreatic beta-cells associated with a lymphocytic infiltrate (insulitis), with autoantibodies to beta-cells being found even before the onset of symptoms. Susceptibility to the disease is strongly influenced by major histocompatibility complex (MHC) class II polymorphism in both man and experimental animal models such as the non-obese diabetic (NOD) mouse. As MHC class II molecules are usually associated with dominant immune responsiveness, it was surprising that introduction of a transgenic class II molecule, I-E, protected NOD mice from insulitis and diabetes. This could be explained by a change either in the target tissue or in the T cells presumed to be involved in beta-cell destruction. Recently, several studies have shown that I-E molecules are associated with ontogenetic deletion of T cells bearing antigen/MHC receptors encoded in part by certain T-cell receptor V beta gene segments. To determine the mechanism of the protective effect of I-E, we have produced cloned CD4+ and CD8+ T-cell lines from islets of recently diabetic NOD mice. These cloned lines are islet-specific and pathogenic in both I-E- and I-E+ mice. Both CD4+ and CD8+ cloned T cells bear receptors encoded by a V beta 5 gene segment, known to be deleted during development in I-E expressing mice. Our data provide, therefore, an explanation for the puzzling effect of I-E on susceptibility to diabetes in NOD mice.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507922     DOI: 10.1038/341326a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  66 in total

1.  Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells.

Authors:  S Ikehara; M Kawamura; F Takao; M Inaba; R Yasumizu; S Than; H Hisha; K Sugiura; Y Koide; T O Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 2.  Genetic analysis of susceptibility to type 1 diabetes.

Authors:  J A Todd
Journal:  Springer Semin Immunopathol       Date:  1992

Review 3.  Molecular mechanisms involved in the etiology and pathogenesis of autoimmune diseases.

Authors:  M Trucco
Journal:  Clin Investig       Date:  1992-09

Review 4.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

Review 5.  The lupus-prone BXSB strain: the Yaa gene model of systemic lupus erythematosus.

Authors:  R Merino; L Fossati; S Izui
Journal:  Springer Semin Immunopathol       Date:  1992

6.  Is there restricted T cell receptor usage in autoimmune disease?

Authors:  A Cooke
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

Review 7.  Molecular biology and coeliac disease.

Authors:  P D Howdle; G E Blair
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

8.  Antigen nonspecific effect of major histocompatibility complex haplotype on autoantibody levels in systemic lupus erythematosus-prone lpr mice.

Authors:  P L Cohen; E Creech; D Nakul-Aquaronne; R McDaniel; S Ackler; R G Rapoport; E S Sobel; R A Eisenberg
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  A comparative study of T-cell receptor V beta usage in non-obese diabetic (NOD) and I-E transgenic NOD mice.

Authors:  N M Parish; H Acha-Orbea; E Simpson; S X Qin; T Lund; A Cooke
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

10.  Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice.

Authors:  A Amrani; J Verdaguer; B Anderson; T Utsugi; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.